PubHawk
Acta Neuropathol Commun July 2019 PMID 31277709

Nanomedicine-driven neuropathic pain relief in a rat model is associated with macrophage polarity and mast cell activation.

Muzamil Saleem, Brooke Deal, Emily Nehl, Jelena M Janjic, John A Pollock

Full text PDF Download social card

Mentions

3
Peak: 2 in Jul 2019
across 2 sources since Jul 2019

Extended reach

2,772
potential audience

Total likes

11

Video views

1,374

Mentions per month

Jul 2019 – Sep 2019

Where it's discussed

  • X / Twitter2 posts
  • YouTube1 videos

AI synopsis

What people are saying

Overall, discussions focus on the promising aspects of nanomedicine in treating neuropathic pain, with posts highlighting how the modulation of immune responses could lead to new therapies. Words like 'significant' and phrases such as 'long-lasting relief' reflect optimism about the research's potential impact and mechanisms, suggesting a shared recognition of the study's scientific and clinical relevance.

AgreementModerate agreement

The discussions generally acknowledge the article's findings, with commenters recognizing the significance of nanomedicine and immune response modulation in pain relief.

InterestModerate interest

Participants show a moderate level of interest, mentioning specific mechanisms like macrophage polarization and mast cell activation, indicating curiosity about the scientific details.

EngagementModerate engagement

Posts reference parts of the study, such as immune responses over time and the therapeutic potential, demonstrating a moderate depth of discussion.

ImpactModerate impact

The comments suggest that the research could influence future pain management strategies by highlighting immune modulation, indicating perceived significance.

Abstract in brief

  • This study investigates how a nanoemulsion-based nanomedicine containing celecoxib can provide long-lasting relief from neuropathic pain in rats by affecting immune responses—specifically macrophage and mast cell activity—in the sciatic nerve and dorsal root ganglia over time.
  • The results show that the nanomedicine rapidly reduces pain within 24 hours, and this relief correlates with decreased immune cell infiltration and activation at the nerve site, especially around day 12 post-surgery, but effects in the dorsal root ganglia are more variable, with some immune responses increasing again by day 18.
  • The therapeutic effect is linked to modulation of macrophage polarity, shifting from a proinflammatory (M1) to an anti-inflammatory (M2) state, and decreased production of inflammatory molecules like COX2 and PGE2 at day 12, but these effects are temporary and revert by day 18.
Read the full abstract

Top posts

Most liked on X and Bluesky
McNeilly Media
@McNeillyMedia · X

New post: Nanomedicine-driven neuropathic pain relief in a rat model is associated with macrophage polarity … https://t.co/v3ndG5WzBO

Jul 6, 2019 · 1,231 followers View post →
MyNeuroNews.com
@MyNeuroNewscom · X

(Nanomedicine-driven neuropathic pain relief in a rat model is associated with ...) has been published on MyNe ... - https://t.co/hoYZcYhkYK

Jul 6, 2019 · 167 followers View post →

All mentions

McNeilly Media
@McNeillyMedia · X

New post: Nanomedicine-driven neuropathic pain relief in a rat model is associated with macrophage polarity … https://t.co/v3ndG5WzBO

Jul 6, 2019 · 1,231 followers View post →
MyNeuroNews.com
@MyNeuroNewscom · X

(Nanomedicine-driven neuropathic pain relief in a rat model is associated with ...) has been published on MyNe ... - https://t.co/hoYZcYhkYK

Jul 6, 2019 · 167 followers View post →